The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

Other key accomplishments and milestones in 2024 include: Metastatic Pancreatic Ductal Adenocarcinoma Commenced enrollment ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...